Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1733 Inhibitors

Olr1733 inhibitors represent a distinct chemical class of compounds that specifically target the Olr1733 protein, which belongs to the olfactory receptor family. These receptors are part of the G protein-coupled receptor (GPCR) superfamily, which play crucial roles in signal transduction across cell membranes. Olr1733, in particular, is associated with the perception of odor molecules, functioning as a sensor that detects specific ligands in the environment. The inhibition of Olr1733 is achieved by compounds that bind to the active or allosteric sites of the receptor, thereby preventing the normal activation of the receptor by its natural ligands. These inhibitors are characterized by their structural diversity, which includes both small organic molecules and larger, more complex entities, reflecting the versatility required to achieve specificity and potency in their inhibitory action.

The study of Olr1733 inhibitors involves a detailed understanding of the receptor's structure, including its transmembrane domains, ligand-binding sites, and the conformational changes it undergoes upon activation. Structural analyses often utilize techniques such as X-ray crystallography or cryo-electron microscopy to elucidate the binding interactions at an atomic level. Computational methods, including molecular docking and dynamics simulations, further aid in predicting the binding affinities and inhibitory mechanisms of these compounds. Additionally, the development of Olr1733 inhibitors is informed by structure-activity relationship (SAR) studies, which correlate specific chemical modifications with changes in inhibitory potency. These studies are essential for optimizing the molecular properties of the inhibitors, such as selectivity, binding affinity, and metabolic stability, thereby advancing the understanding of how chemical inhibition can modulate olfactory receptor functions at the molecular level.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, potentially affecting protein degradation pathways relevant to Olr1733.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multi-kinase inhibitor, could affect angiogenesis and cell proliferation pathways impacting Olr1733.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src family kinase inhibitor, potentially altering cell proliferation and survival pathways affecting Olr1733.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR tyrosine kinase inhibitor, could disrupt signaling pathways that regulate Olr1733 activity.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

BCR-ABL tyrosine kinase inhibitor, might influence signaling pathways regulating Olr1733.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially modulating signaling pathways relevant to Olr1733's function.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL kinase inhibitor, could impact cell proliferation and survival pathways influencing Olr1733.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, might modulate cell cycle regulation pathways impacting Olr1733.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits multiple tyrosine kinases, potentially affecting pathways influencing Olr1733, like angiogenesis or cell proliferation.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, could disrupt several signaling pathways involving Olr1733.